Part D’s Effect On Generic Statins; More ASHE In Brief
• By The Pink Sheet
Statins are primary Part D generic casualty: The Medicare Part D prescription drug benefit had negligible impact on generic utilization rates, according to a preliminary analysis of Walgreens claim data by James Zhang, Virginia Commonwealth University, and colleagues. In a June 23 presentation at the American Society of Health Economists meeting in Durham, N.C., Zhang reports that the odds ratio of generic utilization for Medicare eligible patients, defined as subjects ages 67-73 in 2006, relative to non-Medicare seniors, subjects ages 61-63, was .98. Authors estimate that potential costs to Medicare due to foregone generic substitutions were $2.1 billion in 2006. Antihyperlipidemics is the only drug class with statistically higher generic utilization for the Medicare-eligible population, the authors report. Merck's blockbuster cholesterol agent Zocor (simvastatin) was a primary focus of insurer generic substitution efforts when the statin lost market exclusivity in June 2006, the first year of the drug benefit (1"The Pink Sheet," July 30, 2007, p. 16). In a separate presentation at ASHE, IMS Health Senior VP-Corporate Strategy Murray Aitken reports that generics account for the same percentage of scripts inside and outside of Part D
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
The EU product information for Novo Nordisk’s semaglutide medicines is to be updated to include non-arteritic anterior ischemic optic neuropathy as a side effect with a frequency of “very rare.”
Experts from EUCOPE explain why the Council of the EU’s position on the proposed overhaul of the general pharmaceutical legislation could offer more predictability for companies than the commission’s initial offering.